Abstracts tagged "risk assessment and systemic lupus erythematosus (SLE)"

Abstract Number: 777 • 2018 ACR/ARHP Annual Meeting
Electrocardiographic Abnormalities Are Associated with the Occurrence of Strokes in Systemic Lupus Erythematosus
Thania Perez¹, Christopher Depender², Jianhua Li³ and Laura Geraldino-Pardilla⁴, ¹Columbia University, College of Physicians & Surgeons, New York, NY, ²Medicine/Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ⁴Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Electrocardiographic Abnormalities Are Associated with the Occurrence of Strokes in Systemic Lupus Erythematosus Background/Purpose: Systemic lupus erythematosus (SLE) patients have a 10-fold higher risk for…
Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 723 • 2017 ACR/ARHP Annual Meeting
Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up
Carolinne Monção¹, Leticia Martins¹, Marcela Penteado¹, Rodrigo Reis², Fabiana Miranda Moura dos Santos³, CRISTINA COSTA LANNA³, Antônio Luiz Ribeiro⁴ and Rosa Weiss Telles⁴, ¹Hospital das Clinicas, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, ²Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, ³Medical School, Universidade Federal of Minas Gerais, Brazil, Belo Horizonte, Brazil, ⁴Medical School, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: To evaluate the incidence and variability of traditional coronary artery disease (CAD) risk factors in a cohort of systemic lupus erythematosus (SLE) patients. Methods:…
Abstract Number: 2813 • 2016 ACR/ARHP Annual Meeting
Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
Laurence S Magder¹, Erik Barr² and Michelle Petri³, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at elevated risk for lupus nephritis and ultimately renal failure. While some risk factors for renal…
Abstract Number: 985 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study
Kateryna Vostretsova¹, Sharan K. Rai², Eric C. Sayre³, Hyon K. Choi⁴, JM Esdaile⁵ and J Antonio Avina-Zubieta⁶, ¹Rheumatology, Arthritis Research Centre, Vancouver, BC, Canada, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of mortality. However, recent mortality trends of SLE are unknown, particularly at the general…
Abstract Number: 693 • 2014 ACR/ARHP Annual Meeting
Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea
In-Woon Baek¹, Ki-Jo Kim², Yune-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul-Soo Cho¹, ¹Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, ²Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: To determine the factors associated with occurrence of acute myocarditis (AMC) and its outcomes in patients with systemic lupus erythematosus (SLE). Methods: This was…
Abstract Number: 2423 • 2012 ACR/ARHP Annual Meeting
Perceptions Regarding Cardiovascular Risk Factors and Barriers to Risk Reduction Among African American Women with Lupus
Barron Mia¹, Lynne Nemeth¹, Diane L. Kamen² and Youlanda C. Gibbs¹, ¹College of Nursing, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Cardiovascular disease (CVD) is highly prevalent among African American (AA) women diagnosed with systemic lupus erythematosus (SLE). Studies have suggested that CVD risk factors…
Abstract Number: 980 • 2012 ACR/ARHP Annual Meeting
Genomewide Association Study in Systemic Lupus Erythematosus: Known Loci
Antonio Fernandez-Nebro¹, Patricia E. Carreira², Ricardo Blanco³, Victor M. Martinez-Taboada⁴, Luis Carreño⁵, Alejandro Olive⁶, José Luis Andreu⁷, Mª Angeles Aguirre⁸, Paloma Vela⁹, Jose Javier Pérez Venegas¹⁰, Jose Luís Marenco¹¹, Joan Miquel Nolla¹², Antonio Zea¹³, José M. Pego-Reigosa¹⁴, Mercedes Freire González¹⁵, Gabriela Ávila¹⁶, María América López-Lasanta¹⁶, Raül Tortosa¹⁶, Antonio Julià¹⁶ and Sara Marsal¹⁶, ¹Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ²Rheumatology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ³Rheumatology, Hospital Universitario Marques De Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ⁵Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁶Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁷Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁸Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁹Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, ¹¹Rheumatology, HU Puerta de Hierro Majadahonda, Madrid, Spain, ¹²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁴Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ¹⁵Rheumatology, Complejo Hospitalario Universitario de La Coruña,, La Coruña, Spain, ¹⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with an estimated prevalence of 40:100,000 cases in European populations. SLE has a strong genetic…
Abstract Number: 647 • 2012 ACR/ARHP Annual Meeting
Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Murray B. Urowitz¹, Dominique Ibanez¹, D. D. Gladman², SLICC³ and Systemic Lupus International Collaborating Clinics (SLICC)³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose : There is a high prevalence of premature atherosclerosis among patients with SLE, with a risk 7-9 times that of the general population. The…
Abstract Number: 2685 • 2012 ACR/ARHP Annual Meeting
Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies
Marko Yurkovich¹, Kateryna Vostretsova² and J. Antonio Avina-Zubieta³, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE), is a chronic autoimmune condition. It has the potential to affect any organ system and can be associated with severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].